PharmExec Top50 2011

40 PHARMACEUTICAL EXECUTIVE PHARMACEUTICAL EXECUTIVE
Will the recent wave of megamergers and a slow revival of biotech ?nancing be enough to counter a looming storm surge of patent expirations? US health reform is the next big game-changer, as companies seek a balance between earning pro?ts and placating a restive new breed of payers and the ever-expectant patient
By Jerry Cacciotti and Patrick Clinton

MAY 2011 https://www.wendangku.net/doc/a715791776.html,
41
Revenue Distribution of Top 50
10%
8%
Top 10 accounts for $352.5 billion in sales, which is 59.40% of total revenues of the Top 50 Top 20 accounts for $483.8 billion in sales, which is 81.53% of total revenues of the Top 50
* Figures are rounded
6%
4%
2%
0%
T
he Pharm Exec 50 ranks the world’s largest pharmaceutical companies by global sales of prescription drugs—a key indicator of market change. After last year’s storm of activity, the 50 set a more placid pace, as major players worked on integrating blockbuster mergers and licked their wounds after the latest round of Phase III failures. Late-phase problems are nothing new, and drug candidates can come back from them, but there was something particularly heartbreaking about the recent crop of dead ends, given the huge unmet medical need associated with these therapies: P zer’s Dimebon and Lilly’s Semagacestat for Alzheimer’s, Merck’s vicriviroc for HIV, and Roche’s ocrelizumab for rheumatoid arthritis, to name just a few. Change was most visible on the macro level. The list of the top 10 companies was shaken up a bit, with Novartis passing Sano -Aventis to move into second place, and Merck jumping from seventh to fourth. It was also the rst year the top company crossed the $50 billion mark in sales of prescrip-
P z N n o ov a er - Av r t is en M e t is G la rc xo S m Ro c k Jo it h he hn A st r K s o a Z li n e n & en Jo ec a hn s Br is t E li o n ol L My A b ill y er s b S q ot t ui b b Te A m va Bo ge eh Ba n r in ge Ta yer r k N o I n gel e d a vo h e N o im r di Da ii c A s t e s k hi S a ll a s nk yo Me E B a G il e a r c k is a i x te d KG r In S ci a A ter e n c na es t io n M y al S e lan Mi rv t su b is C h i e r hi u g a Ta i M e nab e n G e ar in nz i A ll y m e er g F o an r es t CS L U O t CB s C e uka B io l g ge e n e nI de Sh c Wa r n e A ir e r C lcon h C e il c o t ph t a W lo n K D a yow a L u n a t s o n ini p p H ak d b e c o n ko k S u K ir mi in to m Sh io n o Ac ogi t H o av is N y sp ir co a m Ap ed ot S t ex ad a Sa
P Novartis Roche Sano -Aventis zer Merck GlaxoSmithKline Lilly Teva Bayer JohnsonBristol-MyersAmgen NovoIngelheim Baxter International Menarini Forest UCBCelgene Warner Chilcott Hakko Kirin Nycomed AstraZeneca & Johnson Squibb Eli Abbott Boehringer Daiichi Merck KGaAMylanChugai Genzyme CSL Otsuka Shire Cephalon Takeda AstellasEisai Sciences Nordisk Gilead Sankyo Servier Mitsubishi Tanabe Allergan Biogen Idec Alcon Watson Kyowa LundbeckShionogi Dainippon Sumitomo Apotex Actavis Hospira Stad
tion drugs—as P zer, fueled by its acquisition of Wyeth, grew from $45.4 billion in Rx sales to $58.5 billion. Meanwhile, consolidation in the ranks continues to place a premium on size and scale: This was the rst year that it took $2 billion in Rx revenues to join the 50. As recently as 10 years ago, you could make the list with revenues of only $500 million. Overall, the 50 accounted for $593.4 billion in human prescription drug sales in 2010. That represents an increase of nearly 8 percent from 2009, when the total was $550.5 billion. But among the top 10, there was slightly better growth. This year’s group grew its Rx revenues from $319.4 billion in scal 2009 to $352.5 last year—an increase of over 10 percent. A good percentage of that growth was fueled by mergers and acquisitions. In addition to P zer and its 29 percent increase, big gainers included Merck (58 percent growth after its merger with Schering Plough) and Abbott (up nearly 28 percent in the wake of its acquisitions of Solvay and Pira-
mal). But the biggest single-year bump came at a much smaller company: The Irish rm Warner Chilcott last year acquired the pharmaceutical business of Procter & Gamble, including the billion-dollar drug Actonel, and raised its Rx revenues a whopping 111 percent to $2.9 billion. Looming over the year—and the decade—is the shadow of US healthcare reform. Many in pharma feel they have dodged the bullet of new regulation and stand to gain as a projected 30 million previously uninsured Americans nally obtain insurance coverage for healthcare. But the Patient Protection and Affordable Care Act is not the end of the discussion—it’s more like the beginning of an avalanche. The economic forces it sets in motion today will be playing out for payers, patients, providers, and pharma for the foreseeable future, changing the way care is delivered and paid for, creating numerous business threats, but, with luck, ending up with the possibility of getting a better alignment between helping the patient and earning a pro t.

42
PHARMACEUTICAL EXECUTIVE
2011 Rank
Company HQ [website]
2010 Rx Sales
(USD billions) [% change from 2009]
2010 R&D spend
(USD millions)
2010 Top-Selling Drugs
[USD billions]
1 2 3 4 5 6 7 8 9 10
P?zer
New York, New York [p?https://www.wendangku.net/doc/a715791776.html,]
$58.5
[28.9%]
$9,413
Lipitor [10.7] Enbrel [3.3] Lyrica [3.1]
Novartis
Basel, Switzerland [https://www.wendangku.net/doc/a715791776.html,]
$42.0
[9.2%]
$7,100
Diovan/Co-Diovan [6.1] Gleevec/Glivec [1.3] Lucentis [1.5]
Sano?-Aventis
Paris, France [sano?https://www.wendangku.net/doc/a715791776.html,]
$40.3
[–4.1%]
$5,147
Lantus [4.7] Lovenox [3.7] Taxotere [2.8]
Merck
Whitehouse Station, New Jersey [https://www.wendangku.net/doc/a715791776.html,]
$39.8
[58.0%]
$11,000
Singulair [5.0] Remicade [2.7] Januvia [2.4]
Roche
Basel, Switzerland [https://www.wendangku.net/doc/a715791776.html,]
$39.1
[4.1%]
$8,612
Avastin [6.8] MabThera/Rituxan [6.7] Herceptin [5.7]
GlaxoSmithKline
Brentford, England [https://www.wendangku.net/doc/a715791776.html,]
$36.2
[–4.2%]
$6,126
Seretide/Advair [7.9] Pandemic Flu Vaccine [1.8] Flixotide/Flovent [1.2]
AstraZeneca
London, England [https://www.wendangku.net/doc/a715791776.html,]
$33.3
[1.4%]
$4,200
Crestor [5.7] Nexium [5.0] Seroquel [4.1]
Johnson & Johnson
New Brunswick, New Jersey [https://www.wendangku.net/doc/a715791776.html,]
$22.4
[–0.4%]
$4,432
Remicade [4.6] Procrit [1.9] Risperdal [1.5]
Eli Lilly
Indianapolis, Indiana [https://www.wendangku.net/doc/a715791776.html,]
$21.1
[5.4%]
$4,880
Zyprexa [5.0] Cymbalta [3.5] Alimta [2.2]
Abbott
Abbott Park, Illinois [https://www.wendangku.net/doc/a715791776.html,]
$19.9
[27.7%]
$3,724
Humira [6.5] Trilipix/TriCor [1.6] Kaletra [1.3]
* Estimate Figures are rounded
Sources: corporate data (10K’s, annual reports, etc.) and Pharm Exec estimates
N/A = Not Available/Not Applicable
How the listings were compiled: Companies in the Pharm Exec 50 are ranked according to global human prescription drug sales. As far as company documentation allows, generics and vaccines are included; over-the-counter products, royalties, and contract manufacturing revenue are not. In most cases, numbers are taken from annual reports or SEC ?lings for the ?scal year that ended in 2010. For most American and European companies, that means the year ending Dec. 31, 2010; for many Japanese companies, it means the year ending March 31, 2010. In the case of private companies that do not report results, we have made estimates based on available data, including IMS reports. For companies that report in currencies other than US dollars, we have converted their numbers using the midpoint average interbank rate for the last day of the ?scal year. Some charts that accompany this article are based on numbers from IMS Health. These are based on a different methodology and will not be consistent with the ?gures we have compiled from ?nancial ?lings. Percentage growth ?gures should be treated with caution, because they can be affected by ?uctuating exchange rates.

44
PHARMACEUTICAL EXECUTIVE
Global Pharma Sales by Region
Market Share Region USD in Billions
334.8 230.7
Growth from 2009
3.2% 1.8% 13.3% 0.4% 16.3%
Source: IMS Health, MIDAS Source: IMS Health
29.2% 12.4% 42.3% 10.8% 5.3%
North America Europe Asia/Africa/Australia 98.1 Japan 85.7 Latin America 42.0
Worldwide Totals: $791.4
4.2%
Sales represent audited market for pharma products only (Dec. 2009–Dec 2010) IMS ?gures do not account for off-invoice discounts/rebates and can vary from reported mfr sales
Top 25 US Pharma Products by Sales
Product
1 Lipitor 2 Nexium 3 Plavix 4 Advair Diskus 5 Abilify 6 Seroquel 7 Singulair 8 Crestor 9 Actos 10 Epogen 11 Remicade 12 Enbrel 13 Cymbalta 14 Avastin 15 Oxycontin 16 Neulasta 17 Zyprexa 18 Humira 19 Lexapro 20 Rituxan 21 Aricept 22 Lovenox 23 Atripla 24 Copaxone 25 Spiriva Handihaler
2010
7.2 6.3 6.1 4.7 4.7 4.6 4.0 4.4 4.2 4.1 3.7 3.8 3.0 3.5 3.4 3.3 3.2 3.3 3.2 3.3 3.3 3.2 2.8 3.1 3.0 3.1 2.9 3.0 3.0 3.0 2.7 2.9 2.5 2.8 2.8 2.8 2.6 2.5 2.3 2.3 2.8 2.2 1.9 2.2 1.7 2.0 1.7 2010: $307.4
2009
7.6 6.3 5.6 -5.26
% Change
FLAT 8.92 FLAT 15.00 4.76 10.81 26.66 2.94 3.13 3.13 FLAT 14.29 3.33 6.90 FLAT 11.11 16.00 FLAT 7.69 8.7 -17.86 15.79 29.41 17.65 2.36%
Figures (rounded) in US billions
TOTAL US SCRIP MARKET:
2009: $300.3

46
PHARMACEUTICAL EXECUTIVE
2011 Rank
Company HQ [website]
2010 Rx Sales
(USD billions) [% change from 2009]
2010 R&D spend 2010 Top-Selling Drugs
(USD Millions) [USD billions]
11 12 13 14 15 16 17 18 19 20
Bristol-Myers Squibb
New York [https://www.wendangku.net/doc/a715791776.html,]
$19.5
[3.6%]
$3,566
Plavix [6.7]
Teva
Petach Tikva, Israel [https://www.wendangku.net/doc/a715791776.html,]
$16.1
[16.0%]
$933
Copaxone [2.9]
Amgen
Thousand Oaks, California [https://www.wendangku.net/doc/a715791776.html,]
$14.7
[1.8%]
$2,894
Neulasta/Neupogen [4.8]
Bayer
Leverkusen, Germany [https://www.wendangku.net/doc/a715791776.html,]
$14.5
[–3.6%]
$2,320
Betaferon/Betaseron [1.6]
Takeda
Osaka, Japan [https://www.wendangku.net/doc/a715791776.html,]
$14.2
[–0.1%]
$3,198
Actos/Glustin [4.2]
Boehringer Ingelheim
Ingelheim, Germany [https://www.wendangku.net/doc/a715791776.html,]
$12.9
[–10.8%]
$3,056
Spiriva [3.8]
Novo Nordisk
Bagsvaerd, Norway [https://www.wendangku.net/doc/a715791776.html,]
$10.8
[9.9%]
$1,709
NovoRapid [2.1]
Astellas
Tokyo, Japan [https://www.wendangku.net/doc/a715791776.html,]
$10.5
[6.0%]
$2,109
Prograf [1.9]
Daiichi Sankyo
Tokyo, Japan [https://www.wendangku.net/doc/a715791776.html,]
$9.8
[20.0%]
$2,124
Olmesartan [2.6]
Eisai
Tokyo, Japan [https://www.wendangku.net/doc/a715791776.html,]
$8.4
[8.0%]
$1,932
Aricept [3.5]
Sources: corporate data (10K’s, annual reports, etc.) and Pharm Exec estimates
N/A = Not Available/Not Applicable
* Estimate
Figures are rounded

48
PHARMACEUTICAL EXECUTIVE
Top 20 Therapeutic Classes by Spending
Product 2010 2009 % Change
3.72 6.63 1.08 12.66 9.52 -15.60 0.87 9.28 12.19 1.16 5.00 14.28 9.23 -3.17 16.33 -18.84 8.69 2.13 12.5 2.44 2.36%
Source: IMS Health Source: IMS Health
22.3 21.5 1 Oncologics 19.3 18.1 2 Respiratory Agents 18.8 18.6 3 Lipid Regulators 16.9 15 4 Antidiabetes 16.1 14.7 5 Antipsychotics 11.9 14.1 6 Antiulcerants 11.6 11.5 7 Antidepressants 10.6 9.7 8 Autoimmune Diseases 9.2 8.2 9 HIV Antivirals 8.7 8.6 10 Angiotensin II 8.4 8.0 11 Narcotic Analgesics 7.2 6.3 12 ADHD 7.1 6.5 13 Platelet Aggregation Inhibitors 6.1 6.3 14 Erythropoietins 15 Multiple Sclerosis 5.7 4.9 6.9 16 Antiepileptics 5.6 17 Vaccines (Pure, Combo, Other) 5.0 4.6 18 Hormonal Contraceptives 4.8 4.7 19 Anti-Alzheimers 4.5 4.0 20 Immunostimulating Agents 4.2 4.1 TOTAL US SCRIP MARKET: 2010: $307.4 2009: $300.3
Figures (rounded) in USD billions Therapy Class de?ned using ATC-de?ned product groups and synthesized based on proprietary IMS Health de?nitons Immunostimulating Agents excludes interferons
Top 20 Therapeutic Classes by Prescriptions
Class
1 Lipid Regulators 2 Antidepressants 3 Narcotic Analgesics 4 Beta Blockers (Plain & Combo) 5 Ace Inhibitors 6 Antidiabetes 7 Respiratory Agents 8 Anti-ulcerants 9 Diuretics 10 Antiepileptics 11 Tranquilizers 12 Thyroid Preps 13 Calcium Antagonists (Plain & Combo) 14 Antirheumatics 15 Hormonal Contraceptives 16 Angiotensin II 17 Penicillins 18 Macrolides & Similar Type 19 Vitamins & Minerals 20 Hypnotics & Sedatives
TOTAL US SCRIP MARKET:
2010
2009
249.7 246.1 241.0
% Change
2.28 3.05 1.37 14.12 1.81 3.77 0.59 0.96 -0.53 5.55 4.42 1.8 3.16 2.70 -1.70 -0.83 -0.65 6.64 3.01 0.76 1.16%
255.4 253.6 244.3 191.5 167.8 168.7 165.7 165.0 159.0 153.3 152.4 147.1 145.7 131.0 131.7 121.7 115.3 108.6 104.0 107.2 105.3 97.9 94.9 95.0 92.5 92.3 93.9 83.7 84.4 76.1 76.6 73.9 69.3 71.9 69.8 66.0 65.5 2009: 3,949.2
2010: 3,995.2
Rx ?gures (rounded) in millions; Therapy classes de?ned using ATC de?ned product groups and synthesized based on proprietary IMS Health de?nitions

50
PHARMACEUTICAL EXECUTIVE
2011 Rank
Company HQ [website]
2010 Rx Sales
(USD billions) [% change from 2009]
2010 R&D spend 2010 Top-Selling Drugs
(USD Millions) [USD billions]
21 22 23 24 25 26 27 28 29 30
Merck KGaA
Darmstadt, Germany [merck.de]
$7.8
[–0.4%]
$1,547
Rebif [2.2]
Gilead Sciences
Foster City, California [https://www.wendangku.net/doc/a715791776.html,]
$7.4
[14.2%]
$1,073
Atripla [3.0]
Baxter International
Deer?eld, Illinois [https://www.wendangku.net/doc/a715791776.html,]
$5.6
[1.3%]
$915
Advate [1.7]
Mylan
Canonsburg, Pennsylvania [https://www.wendangku.net/doc/a715791776.html,]
$5.2
[7.5%]
$282
EpiPen [0.3]
Servier
Neuilly-sur-Seine [https://www.wendangku.net/doc/a715791776.html,]
$4.9
[6.6%]
$1,226
Coversil [1.5*]
Chugai
Tokyo, Japan [chugai-pharm.co.jp]
$4.6
[1.3%]
$671
Avastin [0.6]
Mitsubishi Tanabe
Osaka, Japan [mt-pharma.co.jp]
$4.4
[2.4%]
$897
Remicade [0.5]
Menarini
Florence, Italy [https://www.wendangku.net/doc/a715791776.html,]
$4.0*
[0.2%]
N/A
Migard/Allegro [0.1*]
Genzyme
Cambridge, Massachusetts [https://www.wendangku.net/doc/a715791776.html,]
$4.0
[2.3%]
$847
Cerezyme [0.7]
Allergan
Irvine, California [https://www.wendangku.net/doc/a715791776.html,]
$4.0
[7.9%]
$805
Botox [1.4]
Sources: corporate data (10K’s, annual reports, etc.) and Pharm Exec estimates
N/A = Not Available/Not Applicable
* Estimate
Figures are rounded

MAY 2011 https://www.wendangku.net/doc/a715791776.html,
51
Top 25 Corporations by U.S. Sales
Product 2010 2009
27.8 19.8 18.3
% Change
-5.75 -5.05 FLAT 18.94 8.33 -2.82 13.22 -9.33 0.78 1.60 1.89 -7.14 7.77 -15.79 -24.05 20.51 20.51 15.00 4.54 21.62 3.12 14.28 6.67 7.14 6.82
26.2 1 P?zer 18.8 2 Merck 18.3 3 AstraZeneca 15.7 13.2 4 Novartis 14.3 13.2 5 Lilly 13.8 14.2 6 Roche 13.7 12.1 7 Teva 13.6 15.0 8 GlaxoSmithKline 12.9 12.8 9 Johnson & Johnson 12.7 12.5 10 Amgen 10.8 10.6 11 Abbott 10.4 11.2 12 Sano?-Aventis 9.7 9.0 13 Bristol-Myers Squibb 6.4 7.6 14 Boehringer Ingelheim 6.0 7.9 15 Takeda 4.7 4.4 16 Forest 4.7 3.9 17 Mylan 4.7 3.9 18 Gilead 4.6 4.0 19 Otsuka America 4.6 4.4 20 Eisai 4.5 3.7 21 Novo Nordisk 22 Watson 3.3 3.2 23 Nestle S.A. 3.2 2.8 24 Purdue 3.2 3.0 25 Galen Holdings 3.0 2.8
TOTAL US SCRIP MARKET:
2010: $307.4
2009: $300.3
2.36%
Figures (rounded) in billions
Top 25 Corporations by Prescriptions
Corporation
1 Teva 2 Mylan 3 Novartis 4 P?zer 5 Watson 6 Endo 7 Lupin 8 Merck 9 Amneal 10 AstraZeneca 11 Covidien 12 GlaxoSmithKline 13 Boehringer Ingelheim 14 Actavis U.S. 15 Dr Reddy 16 Abbot 17 Zydus 18 Lilly 19 West Ward 20 Forest 21 Ranbaxy 22 Bristol-Myers Squibb 23 Par 24 Sano?-Aventis 25 Aurobindo
2010
265.3 242.0 233.6 141.0 114.5 134.0 96.2 104.2 123.3 97.9 67.5 86.8 93.8 80.2 91.2 72.6 71.1 68.1 63.5 58.1 53.9 49.5 45.2 44.3 42.5 42.2 40.2 40.0 39.7 379.9 240.9 265.7 235.1
2009
639.3 347.2 629.8
% Change
-8.92 -0.64 -15.49 -7.46 -12.06 -7.16 -1.79 -4.22 -13.60 -4.75 -0.60 -4.11 -4.31 -16.60 -4.99 31.78 37.09 1.51 9.41 10.13 23.14
39.29 45.04
78.2 72.4 71.1 73.5 61.0 34.9 49.8 34.3 46.2 31.0 44.1 48.2 42.1 38.9
54.44
2.06
TOTAL US SCRIP MARKET:
2010: 3,995.2
2009: 3,949.2
1.16%
Figures (rounded) in millions
Top 25 U.S. Pharma Products by Prescriptions
Product
1 hydrocodone/acetaminophen 2 simvastatin 3 lisinopril 4 levothyroxine sodium 5 amlodipine besylate 6 omeprazole (RX) 7 azithromycin 8 amoxicillin 9 metformin HCL 10 hydrochlorothiazide 11 alprazolam 12 Lipitor 13 furosemide 14 metoprolol tartrate 15 zolpidem tartrate 16 atenolol 17 sertraline HCL 18 metoprolol succinate 19 citalopram HBR 20 warfarin sodium 21 oxycodone/acetaminophen 22 ibuprofen (Rx) 23 Plavix 24 gabapentin 25 Singulair
2010
94.1 87.4 70.5 66.0 57.2 51.3 53.4 45.4 52.6 53.8 52.3 52.4 48.3 44.3 47.8 47.9 46.3 43.9 45.3 51.7 43.4 43.5 38.9 41.1 38.0 35.1 36.3 39.3 35.7 34.2 33.0 26.9 32.1 27.1 32.0 31.6 31.9 30.2 31.1 30.3 29.5 29.9 29.3 25.4 28.7 28.6 131.2
2009
83.8 82.8 128.2
% Change
2.34 5.56 6.82 -2.23 -0.19 -0.21 -12.38 -0.23 -5.35 -7.63 4.38 1.27 5.63 2.64 0.35 18.45 5.47 12.29 11.5
17.62
9.03
8.26 22.68
-1.34
15.35
TOTAL US SCRIP MARKET:
2010: 3,995.2
2009: 3,949.2
1.16%
Figures (rounded) in millions
Source: IMS Health
Source: IMS Health
Source: IMS Health

52
PHARMACEUTICAL EXECUTIVE
2011 Rank
Company HQ [website]
2010 Rx Sales
(USD billions) [% change from 2009]
2010 R&D spend 2010 Top-Selling Drugs
(USD Millions) [USD billions]
31 32 33 34 35 36 37 38 39 40
Forest
New York, New York [https://www.wendangku.net/doc/a715791776.html,]
$3.9
[7.4%]
$1,054
Lexapro [2.3]
CSL
Victoria, Australia [https://www.wendangku.net/doc/a715791776.html,.au]
$3.8
[–3.6%]
$272
N/A [N/A]
UCB
Brussels, Belgium [https://www.wendangku.net/doc/a715791776.html,]
$3.7
[–4.0%]
$1,044
Keppra [1.2]
Otsuka
Tokyo, Japan [www.otsuka.co.jp/en/]
$3.6*
[–46.1%]
N/A
Abilify [4.5*]
Celgene
Summit, New Jersey [https://www.wendangku.net/doc/a715791776.html,]
$3.5
[36.7%]
$1,128
Revlimid [2.5]
Biogen Idec
Weston, Massachusetts [https://www.wendangku.net/doc/a715791776.html,]
$3.5
[10.1%]
$1,249
Avonex [3.5]
Shire
Dublin, Ireland [https://www.wendangku.net/doc/a715791776.html,]
$3.1
[16.1%]
$662
Vyvanse [0.6]
Alcon
Hünenberg, Switzerland [https://www.wendangku.net/doc/a715791776.html,]
$3.1
[14.5%]
$747
Glaucoma products [1.3]
Warner Chilcott
Dublin, Ireland [https://www.wendangku.net/doc/a715791776.html,]
$2.9
[111.0%]
$147
Actonel [1.0]
Cephalon
Frazer, Pennsylvania [https://www.wendangku.net/doc/a715791776.html,]
$2.8
[28.3%]
$440
Provigil [1.1]
Sources: corporate data (10K’s, annual reports, etc.) and Pharm Exec estimates
N/A = Not Available/Not Applicable
* Estimate
Figures are rounded

54
PHARMACEUTICAL EXECUTIVE
Top US Patent Expiries
Rank Product/Company
1 2 3 4 5 6 7 8 9 10 11 LIPITOR/P?zer ADVAIR DISKUS/GSK ZYPREXA/Eli Lilly LEVAQUIN/Ortho-McNeil XALATAN/P?zer FEMARA/Novartis ZYPREXA ZYDIS/Eli Lilly ADVAIR HFA/GSK PATANOL/Alcon PATADAY/Alcon VIVELLE-DOT/Novogyne
LOE date
Q4 2011 Q3 2011 Q4 2011 Q2 2011 Q1 2011 Q2 2011 Q4 2011 Q3 2011 Q2 2011 Q2 2011 Q1 2011
2010 Sales
7,244.1 4,711.4 2,957.6 1,522.4 710.8 681.6 331.1 254.6 241.1 215.0 215.0
Total Rx 2010
45.8 19.7 5.3 10.9 6.9 1.3 0.4 1.1 2.3 2.1 3.2
Sales ?gures (rounded) in USD millions; Rx ?gures rounded
LOE = Loss of Exclusivity
Top 20 Global Therapy Classes by Sales
Product
1 Oncologics 2 Lipid Regulators 3 Respiratory Agents 4 Antidiabetics 5 Antiulcerants 6 Angiotensin II Antagonists 7 Antipsychotics 8 Autoimmune Agents 9 Antidepressants 10 HIV Antivirals 11 Platelet Aggreg. Inhibitors 12 Antiepileptics 13 Narcotic Analgesics 14 Cephalosporins & Combs 15 Erythropoietin Products 16 Vaccines 17 Multiple Sclerosis 18 Antirheumatics (Non-steroid) 19 Hormonal Contraception 20 Calcium Antagonists
2010
56.0 36.4 35.8 34.4 27.2 26.6 25.4 20.7 20.2 15.4 14.6 12.6 12.0 11.6 10.6 10.5 9.8 9.8 9.5 9.2
% Change
6.7 2.0 7.0 12.2 -6.7 4.5 9.0 14.7 3.4 13.2 1.5 -3.3 6.4 5.8 -1.8 3.5 13.9 3.6 5.3 -8.8
Source: IMS Health, MIDAS Source: IMS Health, MIDAS
TOTAL US SCRIP MARKET: 2010: $408.3
2009: $384.9
6.10%
Figures (rounded) in USD billions (Dec 2009–Dec 2010) Sales represent audited market for pharma products only IMS ?gures do not account for off-invoice discounts/rebates and can vary from reported mfr sales
Top 20 Leading Global Products by Sales
Product
1 Lipitor (atorvastatin) 2 Plavix (clopidogrel) 3 Seretide (?uticasone/salmeterol) 4 Nexium (esomeprazole) 5 Seroquel (quetiapine) 6 Crestor (rosuvastatin) 7 Enbrel (etanercept) 8 Remicade (in?iximab) 9 Humira (adalimumab) 10 Zyprexa (olanzapine) 11 Avastin (bevacizumab) 12 Singulair (montelukast) 13 Abilify (aripiprazole) 14 Mabthera (rituximab) 15 Lantus (insulin glargine) 16 Aricept (donepezil) 17 Actos (pioglitazone) 18 Lovenox (enoxaparin sodium) 19 Herceptin (trastuzumab) 20 Diovan (valsartan)
2010
12,656.1 8,816.5 8,468.6 8,361.5 6,815.6 6,796.3 6,167.2 6,038.6 5,959.5 5,736.3 5,532.2 5,465.4 5,430.3 5,033.2 4,685.3 4,432.1 4,317.3 4,282.0 4,165.1 4,156.4
% Change
-6.2 -3.4 4.4 1.3 13.2 24 5.2 10.3 19.7 6.6 11.1 9.1 16.3 7.8 16.7 8.5 3.9 -5.3 6.7 3.5
TOTAL US SCRIP MARKET:
2010: $123,315.5
2009: 116,221.7
6.10% Increase
Sales represent audited market for pharma products only
Figures (rounded) in USD millions (Dec. 2009–Dec. 2010) Figures do not account for off-invoice discounts/rebates and can vary from reported mfr sales
Source: IMS Health

56
PHARMACEUTICAL EXECUTIVE
2011 Rank
Company HQ [website]
2010 Rx Sales
(USD billions) [% change from 2009]
2010 R&D spend 2010 Top-Selling Drugs
(USD Millions) [USD billions]
41 42 43 44 45 46 47 48 49 50
Watson
Corona, California [https://www.wendangku.net/doc/a715791776.html,]
$2.6
[27.0%]
$296
CNS generics [0.9]
Lundbeck
Copenhagen, Denmark [https://www.wendangku.net/doc/a715791776.html,]
$2.6
[–0.6%]
$542
Cipralex/Lexapro [1.5]
Kyowa Hakko Kirin
Tokyo, Japan [kyowa-kirin.co.jp]
$2.6
[14.7%]
$429
Nesp/Espo [0.6*]
Dainippon Sumitomo
Osaka, Japan [ds-pharma.co.jp]
$2.6
[20.1%]
$554
Amlodin [0.6]
Shionogi
Osaka, Japan [shionogi.co.jp]
$2.4*
[35.2%]
$135
Crestor [0.3]
Actavis
Hafnarfj?reur, Iceland [https://www.wendangku.net/doc/a715791776.html,]
$2.4*
[32.5%]
N/A
Oxycodone [0.4]
Hospira
Lake Forest, Illinois [https://www.wendangku.net/doc/a715791776.html,]
$2.3
[13.3%]
$301
N/A [N/A]
Nycomed
Zurich, Switzerland [https://www.wendangku.net/doc/a715791776.html,]
$2.2
[–20.2%]
$281
Pantoprazole [1.2]
Apotex
North York, Ontario, Canada [https://www.wendangku.net/doc/a715791776.html,]
$2.1*
[–19.2%]
N/A
N/A [N/A]
Stada
Bad Vilbel, Germany [stada.de]
$2.1
[–5.0%]
$73
Generic omeprazole [0.1]
Sources: corporate data (10K’s, annual reports, etc.) and Pharm Exec estimates
N/A = Not Available/Not Applicable
* Estimate
Figures are rounded
TOTALS:
2010: $593.4 billion
2009: $550.5 billion
7.79%

58
PHARMACEUTICAL EXECUTIVE
The Top 10 Year In Review
1. P?zer President and CEO
Jeff Kindler retired, succeeded by Ian C. Read. George Lorch elected Non-Executive Chairman of the Board. Sutent approved in EU for treatment of pancreatic neuro-endocrine tumors. Launched Prevnar 13, a vaccine against 13 strains of pneumococcal diseases in infants and young children. Also has 118 products in the R&D pipeline and had 1,300 clinical trials in 2010.
4. Merck Elected Kenneth Frazier CEO.
Bought Inspire for $430 million. Rotateq vaccine awarded top honor at Prix Galien USA 2010. Merck BioVentures entered into an alliance with Parexel for biosimilar development. Signed commercialization agreement with Lundbeck for Sycrest and a letter of mutual intent with China’s Sinopharm. Pipeline has more than 20 late-stage candidates. Licensed oral mTOR inhibitor for multiple cancers from Ariad. Oral hepatitis C protease inhibitor Boceprevir granted Priority Review status by FDA.
EU. Kombiglyze XR, the only once-daily dose of DPP4/metformin, developed with Bristol-Myers Squibb, also approved in US. Nine molecules in Phase III trials or submitted for regulatory approval, with another 92 projects in development. Completed deal with Rigel for development of fostamatinib (rheumatoid arthritis).
8. Johnson & Johnson Completed
tender offer for Crucell N.V. in February 2011; acquired 98.93 percent of shares. Products under regulatory review include: Rivaroxoban for stroke prevention in patients with atrial ?brillation (US), Telaprevir for hepatitis C (US and EU), Abiraterone acetate for metastatic advanced prostate (US and EU), and rilpivirine for HIV. Eight more candidates planned for regulatory submission from 2011 to 2013.
Completed purchase of Alcon from Nestlé for $38.5 billion. Jonathan Symonds promoted to CFO. David Epstein replaced CEO Joe Jimenez as Division Head, Pharmaceuticals. Thirteen major pharmaceutical approvals in the US, Europe, and Japan, with 147 products in development. Tasigna was approved in the US, the EU, Japan, and Switzerland for patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML), a form of blood cancer. Menveo (vaccine against meningococcal disease) launched in the US, EU, and parts of Latin America and Asia. Sandoz launched generic enoxaparin, its most successful launch to date, and acquired Oriel Therapeutics.
2. Novartis
Rituxan approved in US as ?rst-line treatment for chronic lymphocytic leukemia (CLL) and relapsed/refractory CLL. Tarceva approved in US and EU for ?rst-line treatment of non-small-cell lung cancer after chemotherapy. FDA rejected use of Avastin as a treatment for metastatic breast cancer; Roche has requested a hearing to appeal this decision. Daniel O’Day appointed COO of the Pharmaceuticals division. Alan Hippe named CFO. Jean-Jacques Garaud appointed Head of Roche Pharma Research and Early Development.
5. Roche
6. GlaxoSmithKline Benlysta
(belimumab, the ?rst new lupus treatment in 60 years) approved by FDA in March. Six products in total approved by US and EU; seven more ?led with regulators. Malaria vaccine in Phase III trials in Africa, with 30 other late-stage assets. Julian Heslop retired as CFO, succeeded by Simon Dingemans. Patents for active ingredients in Seretide/Advair expired.
3. Sano?-Aventis Initiated
acquisition of Genzyme for $16.6 billion (completed in April) and ?nished acquisition of OTC company Chattem. Began collaboration programs with Harvard and Columbia Universities and a research alliance with Scripps Genomic Medicine. Jevtana approved in US for second-line treatment of metastatic hormone-refractory prostate cancer.
Completed acquisition of Alnara and Avid Radiopharmaceuticals. Launched statin Livalo in the US with partner Kowa. Has 68 molecules in development. Several monoclonal antibodies for cancer in late-stage development. Phase III candidates include Necitumumab for non-small-cell lung cancer and Ramucirumab for metastatic breast and gastric cancers. Signed commercialization deal with Acrux for newly approved experimental testosterone solution Axiron.
9. Eli Lilly
10. Abbott The year was marked by
acquisitions, including the pharmaceutical business of Solvay for $6.1 billion plus milestones, and Piramal Healthcare’s Healthcare Solutions business, a leader in the Indian branded generics market, for $2.2 billion in cash, plus $1.6 billion in annual payments through 2014. Additional acquisitions included Advanced Medical Optics, STARLIMS Technologies (informatics), and the remaining shares of Facet Biotech.
Crestor substance patent upheld in US court. Approvals include Vimovo (naproxen/esomeprazole magnesium) in US and EU and Brilique (atherothrombotic event prevention) in
7. AstraZeneca
About the Authors
Jerry Cacciotti is a Partner in Oliver Wyman’s Health and Life Sciences Practice. He can be reached at Jerry.Cacciotti@https://www.wendangku.net/doc/a715791776.html, Patrick Clinton is Marketing Director in the Health & Life Sciences practice of Oliver Wyman. He can be reached at Patrick.Clinton@https://www.wendangku.net/doc/a715791776.html,

29.2% Rank Company 2010 Rx Sales
(USD billions) [% change from 2009]
2010 R&D spend
(USD millions)
2010 Top-Selling Drugs
[USD billions]
12.4% 42.3% 10.8% 5.3%
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50
P?zer Novartis Sano? -Aventis Merck Roche GlaxoSmithKline AstraZeneca Johnson & Johnson Eli Lilly Abbott Bristol-Myers Squibb Teva Amgen Bayer Takeda Boehringer Ingelheim Novo Nordisk Astellas Daiichi Sankyo Eisai Merck KGaA Gilead Sciences Baxter International Mylan Servier Chugai Mitsubishi Tanabe Menarini Genzyme Allergan Forest CSL UCB Otsuka Celgene Biogen Idec Shire Alcon Warner Chilcott Cephalon Watson Lundbeck Kyowa Hakko Kirin Dainippon Sumitomo Shionogi Actavis Hospira Nycomed Apotex Stada
$58.5 $42.0 $40.3 $39.8 $39.1 $36.2 $33.3 $22.4 $21.1 $19.9
[28.9%]
$9,413 $7,100 $5,147 $11,000 $8,612 $6,126 $4,200 $4,432 $4,880 $3,724 $3,566 $933 $2,894 $2,320 $3,198 $3,056 $1,709 $2,109 $2,124 $1,932 $1,547 $1,073 $915 $282 $1,226 $671 $897 N/A $847 $805 $1,054 $272 $1,044 N/A $1,128 $1,249 $662 $747 $147 $440 $296 $542 $429 $554 $135 N/A $301 $281 N/A $73
Lipitor [10.7] Enbrel [3.3] Lyrica [3.1] Diovan/Co-Diovan [6.1] Gleevec/Glivec [1.3] Lucentis [1.5] Lantus [4.7] Lovenox [3.7] Taxotere [2.8] Singulair [5.0] Remicade [2.7] Januvia [2.4] Avastin [6.8] MabThera/Rituxan [6.7] Herceptin [5.7] Seretide/Advair [7.9] Pandemic Flu Vaccine [1.8] Flixotide/Flovent [1.2] Crestor [5.7] Nexium [5.0] Seroquel [4.1] Remicade [4.6] Procrit [1.9] Risperdal [1.5] Zyprexa [5.0] Cymbalta [3.5] Alimta [2.2] Humira [6.5] Trilipix/TriCor [1.6] Kaletra [1.3] Plavix [6.7] Copaxone [2.9] Neulasta/Neupogen [4.8] Betaferon/Betaseron [1.6] Actos/Glustin [4.2] Spiriva [3.8] NovoRapid [2.1] Prograf [1.9] Olmesartan [2.6] Aricept [3.5] Rebif [2.2] Atripla [3.0] Advate [1.7] EpiPen [0.3] Coversil [1.5*] Avastin [0.6] Remicade [0.5] Migard/Allegro [0.1*] Cerezyme [0.7] Botox [1.4] Lexapro [2.3] N/A [N/A] Keppra [1.2] Abilify [4.5*] Revlimid [2.5] Avonex [3.5] Vyvanse [0.6] Glaucoma products [1.3] Actonel [1.0] Provigil [1.1] CNS generics [0.9] Cipralex/Lexapro [1.5] Nesp/Espo [0.6*] Amlodin [0.6] Crestor [0.3] Oxycodone [0.4] N/A [N/A] Pantoprazole [1.2] N/A [N/A] Generic omeprazole [0.1]
* Estimate Figures are rounded
North America Europe Asia/Africa/Australia 98.1 Japan 85.7 Latin America 42.0
334.8 230.7
3.2% 1.8% 13.3% 0.4% 16.3%
Worldwide Totals: $791.4
4.2%
Sales represent audited market for pharma products only (Dec. 2009–Dec 2010) IMS ?gures do not account for off-invoice discounts/rebates and can vary from reported mfr sales
[9.2%]
Top 25 US Pharma Products by Sales
Product 2010
1 Lipitor 2 Nexium 3 Plavix 4 Advair Diskus 5 Abilify 6 Seroquel 7 Singulair 8 Crestor 9 Actos 10 Epogen 11 Remicade 12 Enbrel 13 Cymbalta 14 Avastin 15 Oxycontin 16 Neulasta 17 Zyprexa 18 Humira 19 Lexapro 20 Rituxan 21 Aricept 22 Lovenox 23 Atripla 24 Copaxone 25 Spiriva Handihaler
[–4.1%]
2009
5.6 6.3 7.6
% Change
-5.26 FLAT 8.92 FLAT
[58.0%]
[4.1%]
[–4.2%]
[1.4%]
[–0.4%]
4.7 4.7 4.6 4.0 4.4 4.2 4.1 3.7 3.8 3.0 3.5 3.4 3.3 3.2 3.3 3.2 3.3 3.3 3.2 2.8 3.1 3.0 3.1 2.9 3.0 3.0 3.0 2.7 2.9 2.5 2.8 2.8 2.8 2.6 2.5 2.3 2.3 2.8 2.2 1.9 2.2 1.7 2.0 1.7
6.3 6.1
7.2
15.00 4.76 10.81
-17.86
15.79 17.65
29.41
Figures (rounded) in US billions
[5.4%]
Top 25 Corporations by U.S. Sales
Product 2010
1 P?zer 2 Merck 3 AstraZeneca 4 Novartis 5 Lilly 6 Roche 7 Teva 8 GlaxoSmithKline 9 Johnson & Johnson 10 Amgen 11 Abbott 12 Sano?-Aventis 13 Bristol-Myers Squibb 14 Boehringer Ingelheim 15 Takeda 16 Forest 17 Mylan 18 Gilead 19 Otsuka America 20 Eisai 21 Novo Nordisk 22 Watson 23 Nestle S.A. 24 Purdue 25 Galen Holdings
26.2 18.8 18.3 15.7 13.2 14.3 13.2 13.8 14.2 13.7 12.1 13.6 15.0 12.9 12.8 12.7 12.5 10.8 10.6 10.4 11.2 9.7 9.0 6.4 7.6 6.0 7.9 4.7 4.4 4.7 3.9 4.7 3.9 4.6 4.0 4.6 4.4 4.5 3.7 3.3 3.2 3.2 2.8 3.2 3.0 3.0 2.8
2009
19.8 18.3 27.8
% Change
-5.75 -5.05 FLAT 8.33 13.22 0.78 1.60 1.89 7.77 6.82 15.00 18.94
[27.7%]
Sources: corporate data (10K’s, annual reports, etc.) and Pharm Exec estimates
N/A = Not Available/Not Applicable
Sales ?gures (rounded) in USD millions; Rx ?gures rounded
LOE = Loss of Exclusivity
The insight to tackle what’s next
The pharmaceutical supply chain is the link between the laboratory and the marketplace. Supply chain leaders understand that the conventional, EORFNEXVWHUGULYHQ VXSSO\ FKDLQ PRGHO LV TXLFNO\ FKDQJLQJ %\  ELRSKDUPD ZLOO UHO\ RQ D VXSSO\ FKDLQ WKDW LV H[LEOH FROODERUDWLYH DQG VHJPHQWHG DQG RQH ZKHUH WKH PRYHPHQW RI LQIRUPDWLRQ LV DV LPSRUWDQW DV WKH PRYHPHQW RI SURGXFW LQ VKRUW D VXSSO\ FKDLQ WKDW FDQ SURYLGH FRPSHWLWLYHbGLIIHUHQWLDWLRQ PwC’s latest Pharma 2020 report, Supplying the Future: which path will you take? LGHQWL HV DQG HYDOXDWHV WKH FULWLFDO WUHQGV WKDW ZLOO KHOS VKDSH WKH SKDUPDFHXWLFDO LQGXVWU\ RYHU WKH QH[W GHFDGH )RU PRUH LQIRUPDWLRQ RQ KRZ ZH FDQ KHOS \RXU RUJDQL]DWLRQ RU WR REWDLQ D FRS\ RI WKH 3KDUPD  UHSRUWV YLVLW SZFFRPSKDUPD 7R YLHZ WKH ZHEFDVW YLVLW ZZZSKDUPH[HFFRPVXSSO\FKDLQ
? 2011 PwC. All rights reserved. “PwC” and “PwC US” refers to PricewaterhouseCoopers LLP, a Delaware limited liability partnership, which is a member ?rm of PricewaterhouseCoopers International Limited, each member ?rm of which is a separate legal entity. This document is for general information purposes only, and should not be used as a substitute for consultation with professional advisors.
Source: IMS Health
$19.5 [3.6%] $16.1 [16.0%] $14.7 [1.8%] $14.5 [–3.6%] $14.2 [–0.1%] $12.9 [–10.8%] $10.8 [9.9%] $10.5 [6.0%] $9.8 [20.0%] $8.4 [8.0%] $7.8 [–0.4%] $7.4 [14.2%] $5.6 [1.3%] $5.2 [7.5%] $4.9 [6.6%] $4.6 [1.3%] $4.4 [2.4%] $4.0* [0.2%] $4.0 [2.3%] $4.0 [7.9%] $3.9 [7.4%] $3.8 [–3.6%] $3.7 [–4.0%] $3.6* [–46.1%] $3.5 [36.7%] $3.5 [10.1%] $3.1 [16.1%] $3.1 [14.5%] $2.9 [111.0%] $2.8 [28.3%] $2.6 [27.0%] $2.6 [–0.6%] $2.6 [14.7%] $2.6 [20.1%] $2.4* [35.2%] $2.4* [32.5%] $2.3 [13.3%] $2.2 [–20.2%] $2.1* [–19.2%] $2.1 [–5.0%]
-2.82 -9.33
-7.14 -24.05 -15.79
20.51 20.51 21.62
4.54 3.12 6.67 7.14
14.28
Top 20 Global Therapy Classes by Sales
Product 2010
1 Oncologics 2 Lipid Regulators 3 Respiratory Agents 4 Antidiabetics 5 Antiulcerants 6 Angiotensin II Antagonists 7 Antipsychotics 8 Autoimmune Agents 9 Antidepressants 10 HIV Antivirals 11 Platelet Aggreg. Inhibitors 12 Antiepileptics 13 Narcotic Analgesics 14 Cephalosporins & Combs 15 Erythropoietin Products 16 Vaccines 17 Multiple Sclerosis 18 Antirheumatics (Non-steroid) 19 Hormonal Contraception 20 Calcium Antagonists
Figures (rounded) in billions
% Change
56.0 6.7 2.0 7.0 -6.7 4.5 3.4 -3.3 -1.8 1.5 6.4 5.8 3.5 3.6 5.3 13.9
15.4 14.6 12.6 12.0 11.6 10.6 10.5 9.8 9.8 9.5 9.2
20.7 20.2
27.2 26.6 25.4
36.4 35.8 34.4
12.2
9.0
14.7
Source: IMS Health, MIDAS Source: IMS Health, MIDAS
13.2
-8.8
Figures (rounded) in USD billions (Dec 2009–Dec 2010) Sales represent audited market for pharma products only IMS ?gures do not account for off-invoice discounts/rebates and can vary from reported mfr sales
Top 20 Leading Global Products by Sales
1 Lipitor (atorvastatin) 2 Plavix (clopidogrel) 3 Seretide (?uticasone/salmeterol) 4 Nexium (esomeprazole) 5 Seroquel (quetiapine) 6 Crestor (rosuvastatin) 7 Enbrel (etanercept) 8 Remicade (in?iximab) 9 Humira (adalimumab) 10 Zyprexa (olanzapine) 11 Avastin (bevacizumab) 12 Singulair (montelukast) 13 Abilify (aripiprazole) 14 Mabthera (rituximab) 15 Lantus (insulin glargine) 16 Aricept (donepezil) 17 Actos (pioglitazone) 18 Lovenox (enoxaparin sodium) 19 Herceptin (trastuzumab) 20 Diovan (valsartan)
Product
2010
8,816.5 8,468.6 8,361.5 6,815.6 6,796.3 6,167.2 6,038.6 5,959.5 5,736.3 5,532.2 5,465.4 5,430.3 5,033.2 4,685.3 4,432.1 4,317.3 4,282.0 4,165.1 4,156.4
12,656.1
-6.2 -3.4
% Change
4.4 1.3 5.2
13.2 10.3 11.1 9.1
24 19.7
6.6
7.8 3.9 3.5 8.5 6.7
16.3 16.7
-5.3
Sales represent audited market for pharma products only
Figures (rounded) in USD millions (Dec. 2009–Dec. 2010) Figures do not account for off-invoice discounts/rebates and can vary from reported mfr sales
Top US Patent Expiries
Rank
1 2 3 4 5 6 7 8 9 10 11
Product/Company
LOE date
Q4 2011 Q3 2011 Q4 2011 Q2 2011 Q1 2011 Q2 2011 Q4 2011 Q3 2011 Q2 2011 Q2 2011 Q1 2011
2010 Sales
2,957.6 4,711.4 7,244.1 5.3 10.9 6.9 1.3 0.4 1.1 2.3 2.1 3.2
Total Rx 2010
19.7 45.8
LIPITOR/P?zer ADVAIR DISKUS/GSK ZYPREXA/Eli Lilly LEVAQUIN/Ortho-McNeil XALATAN/P?zer FEMARA/Novartis ZYPREXA ZYDIS/Eli Lilly ADVAIR HFA/GSK PATANOL/Alcon PATADAY/Alcon VIVELLE-DOT/Novogyne
1,522.4 710.8 681.6 331.1 254.6 241.1 215.0 215.0
Source: IMS Health
Source: IMS Health
2.94 3.13 3.13 FLAT 14.29 3.33 6.90 FLAT 11.11 16.00 FLAT 7.69 8.7
26.66
Source: IMS Health, MIDAS
12TH ANNUAL 2
Global Pharma Sales by Region
Market Share
Region
USD in Billions
Growth from 2009

Pull-Out Poster
Sponsored by: